Lipoxin A4 levels correlate with severity in a Spanish COVID-19 cohort: potential use of endogenous pro-resolving mediators as biomarkers
BackgroundSARS-CoV-2, the causative virus of the COVID-19 global pandemic, leads to a wide variety of responses among patients. Some of them present a very severe phenotype, while others only experience mild symptoms or are even asymptomatic. This differential prognosis is tightly related to the inf...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1509188/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832591039104286720 |
|---|---|
| author | Sergio Sánchez-García Rafael I. Jaén Roberto Lozano-Rodríguez José Avendaño-Ortiz Alejandro Pascual‐Iglesias Laura Hurtado-Navarro Eduardo López-Collazo Eduardo López-Collazo Lisardo Boscá Lisardo Boscá Patricia Prieto Patricia Prieto Patricia Prieto |
| author_facet | Sergio Sánchez-García Rafael I. Jaén Roberto Lozano-Rodríguez José Avendaño-Ortiz Alejandro Pascual‐Iglesias Laura Hurtado-Navarro Eduardo López-Collazo Eduardo López-Collazo Lisardo Boscá Lisardo Boscá Patricia Prieto Patricia Prieto Patricia Prieto |
| author_sort | Sergio Sánchez-García |
| collection | DOAJ |
| description | BackgroundSARS-CoV-2, the causative virus of the COVID-19 global pandemic, leads to a wide variety of responses among patients. Some of them present a very severe phenotype, while others only experience mild symptoms or are even asymptomatic. This differential prognosis is tightly related to the inflammatory status of the patient. Although WHO declared the end of the emergency, the pandemic caused a great socio-sanitary impact in all countries. Thus, the possible outbreak of new biological diseases in the future makes it necessary to deepen the knowledge of this uncontrolled immune response and look for reliable biomarkers to help us predict its potential health impact. Specialized pro-resolving lipid mediators (SPMs) as lipoxins are endogenous mediators synthesized from arachidonic acid in the resolution stage of any inflammatory process. These lipids have pro-resolving actions in several pathological models, including reducing NF-κB-mediated inflammation, and inducing the antioxidant response through the Nrf-2 pathway. Thus, although a potential relationship has already been suggested between low levels of SPMs and COVID-19 severity, their true role as a predictive biomarker is still unknown.Methods and resultsIn this study, we have analyzed by ELISA the serum levels of lipoxin A4 (LXA4) in a representative Spanish cohort. We found reduced levels in deceased patients when compared to mild or severe patients, concomitant with a decrease in the LXA4 biosynthetic pathway and an increase in its degradation pathway. Furthermore, we have studied the correlation between the levels of this SPM and several pathology indicators, finding a significant correlation between increased LXA4 levels and a better prognosis of the patients.ConclusionWe propose to measure systemic LXA4 as a new promising biomarker to predict the survival in patients affected by SARS-CoV-2 and presumably to other viruses that can affect humanity in the future. |
| format | Article |
| id | doaj-art-7e3c6118a74e44418ed7b4d69bd9ebd3 |
| institution | Kabale University |
| issn | 1664-3224 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj-art-7e3c6118a74e44418ed7b4d69bd9ebd32025-01-23T05:10:19ZengFrontiers Media S.A.Frontiers in Immunology1664-32242025-01-011510.3389/fimmu.2024.15091881509188Lipoxin A4 levels correlate with severity in a Spanish COVID-19 cohort: potential use of endogenous pro-resolving mediators as biomarkersSergio Sánchez-García0Rafael I. Jaén1Roberto Lozano-Rodríguez2José Avendaño-Ortiz3Alejandro Pascual‐Iglesias4Laura Hurtado-Navarro5Eduardo López-Collazo6Eduardo López-Collazo7Lisardo Boscá8Lisardo Boscá9Patricia Prieto10Patricia Prieto11Patricia Prieto12Departamento de enfermedades metabólicas e inmunitarias, Instituto de Investigaciones Biomédicas “Sols-Morreale”, Madrid, SpainDepartamento de enfermedades metabólicas e inmunitarias, Instituto de Investigaciones Biomédicas “Sols-Morreale”, Madrid, SpainInnate Immune Response Group, Instituto de Investigación del Hospital Universitario La Paz (IdiPaz), Madrid, SpainMicrobiology Department, Hospital Universitario Ramón y Cajal and Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, SpainInnate Immune Response Group, Instituto de Investigación del Hospital Universitario La Paz (IdiPaz), Madrid, SpainInnate Immune Response Group, Instituto de Investigación del Hospital Universitario La Paz (IdiPaz), Madrid, SpainInnate Immune Response Group, Instituto de Investigación del Hospital Universitario La Paz (IdiPaz), Madrid, SpainCentro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, SpainDepartamento de enfermedades metabólicas e inmunitarias, Instituto de Investigaciones Biomédicas “Sols-Morreale”, Madrid, SpainCentro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III, Madrid, SpainDepartamento de enfermedades metabólicas e inmunitarias, Instituto de Investigaciones Biomédicas “Sols-Morreale”, Madrid, SpainCentro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III, Madrid, SpainDepartamento de Farmacología, Farmacognosia y Botánica, Facultad de Farmacia, Universidad Complutense de Madrid, Madrid, SpainBackgroundSARS-CoV-2, the causative virus of the COVID-19 global pandemic, leads to a wide variety of responses among patients. Some of them present a very severe phenotype, while others only experience mild symptoms or are even asymptomatic. This differential prognosis is tightly related to the inflammatory status of the patient. Although WHO declared the end of the emergency, the pandemic caused a great socio-sanitary impact in all countries. Thus, the possible outbreak of new biological diseases in the future makes it necessary to deepen the knowledge of this uncontrolled immune response and look for reliable biomarkers to help us predict its potential health impact. Specialized pro-resolving lipid mediators (SPMs) as lipoxins are endogenous mediators synthesized from arachidonic acid in the resolution stage of any inflammatory process. These lipids have pro-resolving actions in several pathological models, including reducing NF-κB-mediated inflammation, and inducing the antioxidant response through the Nrf-2 pathway. Thus, although a potential relationship has already been suggested between low levels of SPMs and COVID-19 severity, their true role as a predictive biomarker is still unknown.Methods and resultsIn this study, we have analyzed by ELISA the serum levels of lipoxin A4 (LXA4) in a representative Spanish cohort. We found reduced levels in deceased patients when compared to mild or severe patients, concomitant with a decrease in the LXA4 biosynthetic pathway and an increase in its degradation pathway. Furthermore, we have studied the correlation between the levels of this SPM and several pathology indicators, finding a significant correlation between increased LXA4 levels and a better prognosis of the patients.ConclusionWe propose to measure systemic LXA4 as a new promising biomarker to predict the survival in patients affected by SARS-CoV-2 and presumably to other viruses that can affect humanity in the future.https://www.frontiersin.org/articles/10.3389/fimmu.2024.1509188/fullCovidpulmonary diseasecytokine stormlipoxinbiomarker |
| spellingShingle | Sergio Sánchez-García Rafael I. Jaén Roberto Lozano-Rodríguez José Avendaño-Ortiz Alejandro Pascual‐Iglesias Laura Hurtado-Navarro Eduardo López-Collazo Eduardo López-Collazo Lisardo Boscá Lisardo Boscá Patricia Prieto Patricia Prieto Patricia Prieto Lipoxin A4 levels correlate with severity in a Spanish COVID-19 cohort: potential use of endogenous pro-resolving mediators as biomarkers Frontiers in Immunology Covid pulmonary disease cytokine storm lipoxin biomarker |
| title | Lipoxin A4 levels correlate with severity in a Spanish COVID-19 cohort: potential use of endogenous pro-resolving mediators as biomarkers |
| title_full | Lipoxin A4 levels correlate with severity in a Spanish COVID-19 cohort: potential use of endogenous pro-resolving mediators as biomarkers |
| title_fullStr | Lipoxin A4 levels correlate with severity in a Spanish COVID-19 cohort: potential use of endogenous pro-resolving mediators as biomarkers |
| title_full_unstemmed | Lipoxin A4 levels correlate with severity in a Spanish COVID-19 cohort: potential use of endogenous pro-resolving mediators as biomarkers |
| title_short | Lipoxin A4 levels correlate with severity in a Spanish COVID-19 cohort: potential use of endogenous pro-resolving mediators as biomarkers |
| title_sort | lipoxin a4 levels correlate with severity in a spanish covid 19 cohort potential use of endogenous pro resolving mediators as biomarkers |
| topic | Covid pulmonary disease cytokine storm lipoxin biomarker |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1509188/full |
| work_keys_str_mv | AT sergiosanchezgarcia lipoxina4levelscorrelatewithseverityinaspanishcovid19cohortpotentialuseofendogenousproresolvingmediatorsasbiomarkers AT rafaelijaen lipoxina4levelscorrelatewithseverityinaspanishcovid19cohortpotentialuseofendogenousproresolvingmediatorsasbiomarkers AT robertolozanorodriguez lipoxina4levelscorrelatewithseverityinaspanishcovid19cohortpotentialuseofendogenousproresolvingmediatorsasbiomarkers AT joseavendanoortiz lipoxina4levelscorrelatewithseverityinaspanishcovid19cohortpotentialuseofendogenousproresolvingmediatorsasbiomarkers AT alejandropascualiglesias lipoxina4levelscorrelatewithseverityinaspanishcovid19cohortpotentialuseofendogenousproresolvingmediatorsasbiomarkers AT laurahurtadonavarro lipoxina4levelscorrelatewithseverityinaspanishcovid19cohortpotentialuseofendogenousproresolvingmediatorsasbiomarkers AT eduardolopezcollazo lipoxina4levelscorrelatewithseverityinaspanishcovid19cohortpotentialuseofendogenousproresolvingmediatorsasbiomarkers AT eduardolopezcollazo lipoxina4levelscorrelatewithseverityinaspanishcovid19cohortpotentialuseofendogenousproresolvingmediatorsasbiomarkers AT lisardobosca lipoxina4levelscorrelatewithseverityinaspanishcovid19cohortpotentialuseofendogenousproresolvingmediatorsasbiomarkers AT lisardobosca lipoxina4levelscorrelatewithseverityinaspanishcovid19cohortpotentialuseofendogenousproresolvingmediatorsasbiomarkers AT patriciaprieto lipoxina4levelscorrelatewithseverityinaspanishcovid19cohortpotentialuseofendogenousproresolvingmediatorsasbiomarkers AT patriciaprieto lipoxina4levelscorrelatewithseverityinaspanishcovid19cohortpotentialuseofendogenousproresolvingmediatorsasbiomarkers AT patriciaprieto lipoxina4levelscorrelatewithseverityinaspanishcovid19cohortpotentialuseofendogenousproresolvingmediatorsasbiomarkers |